Skip to main content
search
Tag

Drugs

Jan 30 2014

A brief note from PWC's Health Research Institute assesses the impact on drug manufacturers from the health exchanges, suggesting that there maybe a benefit from more people having insurance, but the size of the benefit may depend on the nature and extent of the drug benefit.

http://www.pwc.com/us/en/health-industries/health-research-institute/assets/PwC-Pharma-FAQ-FINAL.pdf
Jan 30 2014

Gilead's new Hep C drug costs $84,000 for a 12 week course of treatment and PBMs and payers are determined not to pay it.  The latest in the battles over the frightening rise in specialty drug use and spending.

http://www.bloomberg.com/news/2014-01-27/at-84-000-gilead-hepatitis-c-drug-sets-off-payer-revolt.html
Jan 29 2014

Successful techniques for better medication adherence are presented in a JAMA viewpoint, including patient education and counseling, self-monitoring and cost interventions.

http://jama.jamanetwork.com/article.aspx?articleid=1784085
Dec 30 2013

A study published in the Journal of Managed Care Pharmacy finds that statin users who have a copay are less likely to be adherent to their prescription and that those who have no copay on other drugs are less likely to adhere to their statin prescription than to the non-copay drugs.

http://www.amcp.org/JMCP/2014/January/17494/1033.html
Dec 18 2013

PMBI Pharmacy Benefits Report

http://reports.pbmi.com/report.php
Dec 12 2013

According to a survey from Capgemini and QuantiaMD most physicians prefer to get drug information from digital sources as opposed to print material or visits from drug reps.  This actually can result in significant savings to manufacturers as drug reps are costly resources.

http://www.mmm-online.com/researchers-find-reps-increasingly-losing-out/article/324344/
Dec 06 2013

IMS Global Use of Medicines Report

http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf
Dec 06 2013

An AHRQ Statistical Brief examines the top 5 therapeutic classes of drug use for adults in 2010, which were metabolic agents, CNS drugs, cardiovascular, psychiatric and gastrointestinal.  These classes accounted for about $153 billion of spending or 60% of total drug spending.

http://meps.ahrq.gov/mepsweb/data_files/publications/st410/stat410.shtml
Dec 05 2013

AHRQ releases a Statistical Brief showing that the most common sources of adverse drug events during a hospitalization in 2011 were steroids, anticoagulants, antibiotics and narcotics.

http://www.hcup-us.ahrq.gov/reports/statbriefs/sb164.jsp
Close Menu